Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Torres Vedras
Clinical trial register · Portugal

Clinical Trials in Torres Vedras, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1104 matching records held by the registry are in this view. Synced 30 Oct 2026, 03:17 UTC
1104
Studies in scope
all four open statuses
533
Recruiting now
open to new participants
285
Lead sponsors
across recruiting studies
Top sites
Lisbon 689 Porto 537 Coimbra 256 Braga 182 Vila Nova de Gaia 105
Narrow the registerReset
Recruitment status
Phase
Site location
Lisbon689 Porto537 Coimbra256 Braga182 Vila Nova de Gaia105
All 97 locations
Target enrolment
to

Trials with a site in Torres Vedras

16 of 1104 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Portugal
Start
Recruiting
Prilenia
Phase 3
400
Coimbra, Lisbon, Porto, Torres Vedras
2026-07-01
Recruiting
Bristol-Myers Squibb
Phase 3
650
Coimbra, Guimarães, Lisbon, Senhora da Hora, Torres Vedras
2025-12-02
Recruiting
Hoffmann-La Roche
Phase 3
900
Braga, Coimbra, Funchal, Guimarães, Lisbon, Matosinhos Municipality, Torres Vedras
2025-11-24
Recruiting
MapLight Therapeutics
Phase 2
300
Torres Vedras
2025-08-15
Recruiting
Bristol-Myers Squibb
Phase 3
586
Torres Vedras, Matosinhos Municipality, Braga, Coimbra, Guimarães, Porto
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
426
Coimbra, Guimarães, Lisbon, Senhora da Hora, Torres Vedras
2025-07-10
Active, closed
AbbVie
Observational
1,314
Guimarães, Lisbon, Loures, Sintra, Torres Vedras, Coimbra, Porto
2024-11-26
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Guimarães, Lisbon, Torres Vedras, Matosinhos Municipality
2024-09-26
Active, closed
Ferrer Internacional S.A.
Phase 2
241
Braga, Torres Vedras
2024-07-23
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Guimarães, Lisbon, Torres Vedras, Matosinhos Municipality
2023-07-11
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Torres Vedras
2023-06-27
Active, closed
Bial R&D Investments, S.A.
Phase 2
237
Coimbra, Guimarães, Porto, Torres Vedras
2023-03-31
Active, closed
Denali Therapeutics Inc.
Phase 1/2
85
Braga, Torres Vedras
2022-02-01
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Loures, Almada, Braga, Porto, Torres Vedras
2019-08-12
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 31 October 2026. https://priyalifescience.com/clinical-trials-portugal/city/torres-vedras

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,104 studies in total at the last sync on 30 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Torres Vedras.

How many clinical trials are recruiting in Torres Vedras?

8 of the 16 studies on this page are recruiting new participants as of the 30 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Torres Vedras), 16 studies
PhaseStudiesRecruitingShare
Phase 310762.5%
Phase 24125%
Observational106.3%
Phase 1/2106.3%

Most active sponsors

Lead sponsors with the most studies (Torres Vedras)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb33
Hoffmann-La Roche31
Karuna Therapeutics, Inc., a Bristol Myers Squibb company22
AbbVie10
Bial R&D Investments, S.A.10
Denali Therapeutics Inc.10
Ferrer Internacional S.A.10
MapLight Therapeutics11
NeuroDerm Ltd.10
Prilenia11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.